Merck & Co. (MRK)
(Delayed Data from NYSE)
$113.09 USD
-1.64 (-1.43%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $113.01 -0.08 (-0.07%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.09 USD
-1.64 (-1.43%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $113.01 -0.08 (-0.07%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth A Momentum B VGM
Zacks News
Bristol-Myers Gets FTC Clearance for Celgene Acquisition
by Zacks Equity Research
Bristol-Myers (BMY) obtains FTC permission for the Celgene acquisition and will divest Otezla to Amgen.
Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date
by Zacks Equity Research
AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us take a look at the reasons for the same.
5 Blue-Chip Stocks to Buy as Dow Breezes Past 28,000
by Tirthankar Chakraborty
We highlight blue-chip companies slated to gain in the near term as they have large market capitalization, strong balance sheet and solid cash flow.
AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status
by Zacks Equity Research
The FDA grants priority review to AstraZeneca (AZN) and Merck's NDA for MEK 1/2 inhibitor, selumetinib. Additionally, Qtrilmet tablets to treat type-II diabetes get approval in the EU.
Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates
by Kinjel Shah
Merck (MRK) gets approval in Europe for Ebola vaccine. Roche, Glaxo (GSK) & Pfizer (PFE) provide pipeline updates.
4 Big Drugmakers to Bet on After a Great Earnings Season
by Kinjel Shah
Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.
FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes
by Zacks Equity Research
Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.
Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Celldex (CLDX) reports mixed third-quarter results. Its revenues fall on reduced collaboration and contract revenues.
Merck's Ebola Vaccine Gets Conditional Approval in Europe
by Zacks Equity Research
European Commission grants approval to Merck's (MRK) Ervebo (V920) for active immunization of individuals 18 years and above to protect against Ebola Virus Disease caused by Zaire Ebola virus.
Bristol-Myers' Opdivo/Yervoy sBLA for HCC Gets Priority Review
by Zacks Equity Research
Bristol-Myers' (BMY) label expansion application for Opdivo plus Yervoy combo regimen to include patients with hepatocellular carcinoma, a form of liver cancer, makes progress.
Pfizer-Merck KGaA's Bavencio Fails in 2nd Gastric Cancer Study
by Zacks Equity Research
Pfizer (PFE) and Merck KGaA's Bavencio misses the primary goal in a late-stage study evaluating it as the first-line maintenance therapy for patients with metastatic HER2-negative gastric cancer.
The Zacks Analyst Blog Highlights: Mastercard, UnitedHealth, Merck, Qualcomm and CVS Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, UnitedHealth, Merck, Qualcomm and CVS Health
Novartis' Generics Unit to Buy Aspen's Japanese Operations
by Zacks Equity Research
Novartis (NVS) inks a deal to acquire the Japanese business of Aspen Global Incorporated.
Aduro (ADRO) Q3 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Aduro's (ADRO) loss misses estimates in Q3 while revenues almost match the mark.
The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co
by Zacks Equity Research
The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co
Top Analyst Reports for Mastercard, UnitedHealth & Merck
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), UnitedHealth Group (UNH) and Merck (MRK).
Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Nektar's (NKTR) reports encouraging third-quarter results. The company continues to progress with its pipeline candidates. However, the timeline for its pain drug NKTR-181's approval remains uncertain.
Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed third-quarter results.
Trade Deal Delay Unlikely to Hit U.S. Healthcare: 4 Picks
by Zacks Equity Research
The healthcare sector seems to be least affected by a protracted U.S.-China trade war. Stellar third-quarter earnings make the sector a hotbed for money.
Value Biotech ETFs & Stocks to Buy Now
by Sanghamitra Saha
Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.
The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo
Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2020.
Novo Nordisk (NVO) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Novo Nordisk (NVO) beats earnings estimates but misses sales estimates in the third quarter of 2019.
Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates
by Kinjel Shah
Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results.
Medicines Company (MDCO) Incurs Wider-Than-Expected Q3 Loss
by Zacks Equity Research
The Medicines Company (MDCO) misses earnings estimates in Q3. The company is progressing well with its sole pipeline candidate, inclisiran.